Drugmaker Johnson & Johnson on Tuesday asked the US Food and Drug Administration (FDA) to authorize booster shots of its COVID-19 vaccine for people over the age of 18.
Mathai Maimon, global head of research and development at J&J, said, “Our clinical program has found that a booster of our COVID-19 vaccine increases the level of protection for people who have received our single-shot vaccine. has done.”
J&J said that when the booster was given six months after the first shot, “antibody levels rose nine-fold a week after the booster and continued to climb 12-fold more than four weeks after the booster,” regardless of age.
“We look forward to our discussions with the FDA and other health officials to support our decisions regarding the booster,” Maimen said.
President Joe Biden’s administration announced plans in August for Americans vaccinated with the Pfizer and Moderna mRNA vaccines to get a third shot.
Biden personally received a COVID-19 vaccine booster shot last month and told Americans still opposing vaccinations were harming the country.
The president got Pfizer’s third dose in line with recently approved health guidance, which allows boosters for people 65 or older.
Also eligible for a booster are adults with high-risk medical conditions and those in jobs where they are frequently exposed to the virus.
The FDA said Tuesday that its advisory committee will meet on October 14 to discuss emergency use authorization for Moderna booster shots and on October 15 to discuss the J&J booster.
(Except for the title, this story has not been edited by NDTV staff and is published from a syndicated feed.)